PATIENT ALERT: For more information regarding the Coronavirus (COVID-19), Click Here.

Clinical Research & Trials

Available Trials

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.

If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach


Breast Cancer Research

  • USO 17026

    A Phase II, Multicenter, Open-Label, Three-Cohort, Noncomparative Study To Assess The Efficacy And Safety Of Alpelisib Plus Fulvestrant Or Letrozole In Patients With PIK3CA Mutant,Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (Abc), Who Have Progressed On Or After Prior Treatments (CBYL719X2402)

    Available at 1 location

    View Details

  • USO 18238

    A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

    Available at 3 locations

    View Details

  • USO 19009

    A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)

    Available at 3 locations

    View Details

  • USO 18232

    A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)

    Available at 1 location

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 5 locations

    View Details

  • USO 17027

    A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing The Efficacy And Safety Of The Antibody-Drug Conjugate SYD985 To Physician's Choice In Patients With HER2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer (SYD985.002)

    Available at 1 location

    View Details

  • Alliance A011502 (ABC Trial)

    A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer

    Available at 6 locations

    View Details

GYN Cancer Research

  • USO 18269

    Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer ( ENGOT-ov50 / INNOVATE-3)

    Available at 1 location

    View Details

  • USO 17218

    A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With TSR-042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First-Line Treatment Of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)

    Available at 5 locations

    View Details

  • USO 18232

    A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)

    Available at 1 location

    View Details

  • USO 17182

    Clovis A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClovisCO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA)

    Available at 3 locations

    View Details

Genitourinary Cancer Research

  • USO 19094

    Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) (QBGJ398-302)

    Available at 1 location

    View Details

  • USO 17133

    A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) (42756493BLC3001)

    Available at 1 location

    View Details

  • USO 19032

    Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

    Available at 2 locations

    View Details

  • JANSSEN 56021927PCR2032

    JANSSEN 56021927PCR2032: An Open-label, Multicenter, Phase Ib Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Available at 1 location

    View Details

  • USO 17165

    Phase 1b/2 Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations (42756493BLC2002)

    Available at 1 location

    View Details

  • Duke Panther Pro00075097

    Duke Panther Pro00075097: Prospective Study of Apalutamide and Abiraterone Acetate In Chemo Therapy Naïve Men with mCRPC Stratified by Race (Pro00075097)

    Available at 2 locations

    View Details

  • USO 17005

    A Single-Arm, Open-Label, Multicenter Study Of Enfortumab Vedotin (ASG-22CE) For Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy (SGN22E-001)

    Available at 5 locations

    View Details

Leukemia & Lymphoma Research

  • USO 18281

    A Phase 1a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01)

    Available at 1 location

    View Details

Lung Cancer Research

  • USO 19109

    A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (Fl) (C2321001)

    Available at 1 location

    View Details

  • USO 18234

    A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer (AB928CSP0004)

    Available at 1 location

    View Details

Solid Tumors Research

  • USO 19079

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (INCB 54828-207)

    Available at 2 locations

    View Details

  • LOXO-EXT-17005

    LOXO-EXT-17005: Phase 1/2 Study Of The TRK Inhibitor LOXO-195 In Adult And Pediatric Subjects With Previously Treated NTRK Fusion Cancers

    Available at 1 location

    View Details

  • USO 18057

    A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

    Available at 1 location

    View Details

  • Ignyta (RXDX 101-02)

    An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    Available at 1 location

    View Details